Related Experiment Video
Updated: May 8, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
HeberNasvac: Development and Application in the Context of Chronic Hepatitis B
Julio C Aguilar1, Sheikh Mf Akbar2, Mamun Al-Mahtab3
1Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Abstract:
The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation.
How To Cite This Article:
Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatitis
Viral Hepatitis I: Introduction
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology
Chronic Pancreatitis I: Introduction

